Drug Trial Radar · NCT07807059
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Mar 15, 2027
Study completion Mar 15, 2027
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8 healthy participants.
Conditions
- Overweight/Obesity
- Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
- Type 2 Diabetes Mellitus
Interventions
HRS-4729Drug
Each subject will receive a single subcutaneous dose of HRS-4729 injection solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: assessed up to approximately 4 weeks post-dose;
- AUC0-tTime frame: assessed up to approximately 4 weeks post-dose
- AUC0-inf.Time frame: assessed up to approximately 4 weeks post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.